Cargando…

Prognosis of rare pathological primary urethral carcinoma

PURPOSE: Urethral carcinoma (UC), as a rare tumor, is not widely studied. There have been no systematic studies of rare pathological types of UC. We conducted this study to further investigate rare pathological types of primary urethral carcinoma (PUC). MATERIALS AND METHODS: We used the population-...

Descripción completa

Detalles Bibliográficos
Autores principales: Abudurexiti, Mierxiati, Wang, Jun, Shao, Ning, Wan, Fang-Ning, Zhu, Yao, Dai, Bo, Ye, Ding-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289122/
https://www.ncbi.nlm.nih.gov/pubmed/30584373
http://dx.doi.org/10.2147/CMAR.S184197
_version_ 1783379927369777152
author Abudurexiti, Mierxiati
Wang, Jun
Shao, Ning
Wan, Fang-Ning
Zhu, Yao
Dai, Bo
Ye, Ding-Wei
author_facet Abudurexiti, Mierxiati
Wang, Jun
Shao, Ning
Wan, Fang-Ning
Zhu, Yao
Dai, Bo
Ye, Ding-Wei
author_sort Abudurexiti, Mierxiati
collection PubMed
description PURPOSE: Urethral carcinoma (UC), as a rare tumor, is not widely studied. There have been no systematic studies of rare pathological types of UC. We conducted this study to further investigate rare pathological types of primary urethral carcinoma (PUC). MATERIALS AND METHODS: We used the population-based Surveillance, Epidemiology, and End Results (SEER) database to evaluate prognostic factors in rare pathological types of PUC. From 1978 to 2015, 2,651 and 257 cases were identified in the SEER database as common and rare pathological types of PUC, respectively. Overall and cancer-specific survival (CSS) times were computed using the Kaplan–Meier method, and the Cox proportional hazards analysis was used to evaluate patient age at diagnosis, gender, race, and TNM stage. RESULTS: The median overall survival (OS) rates were 36 and 59 months for rare and common pathological groups, respectively, and their respective 10-year OS rates were 31.9% and 42.4%, respectively. The median CSS rate was 61 months for the rare pathological group. Through multivariate analysis, it was found that age, race, T stage, and M stage were independent prognostic risk factors for rare pathological type of urethral cancer. In the age group, the HR ratio of patients aged older than 60 years and younger or equal to 60 years was 2.778 (P<0.001). The HR ratio of other races to Whites was 1.444 (P=0.040). In TNM staging, the HR ratio between T3–T4 and Ta–T2 was 2.386 (P=0.046), and the HR value of M1 and M0 was 5.847 (P<0.001). CONCLUSION: Age, race, T stage, and M stage were predictive of OS and CSS in rare pathological PUC.
format Online
Article
Text
id pubmed-6289122
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62891222018-12-24 Prognosis of rare pathological primary urethral carcinoma Abudurexiti, Mierxiati Wang, Jun Shao, Ning Wan, Fang-Ning Zhu, Yao Dai, Bo Ye, Ding-Wei Cancer Manag Res Original Research PURPOSE: Urethral carcinoma (UC), as a rare tumor, is not widely studied. There have been no systematic studies of rare pathological types of UC. We conducted this study to further investigate rare pathological types of primary urethral carcinoma (PUC). MATERIALS AND METHODS: We used the population-based Surveillance, Epidemiology, and End Results (SEER) database to evaluate prognostic factors in rare pathological types of PUC. From 1978 to 2015, 2,651 and 257 cases were identified in the SEER database as common and rare pathological types of PUC, respectively. Overall and cancer-specific survival (CSS) times were computed using the Kaplan–Meier method, and the Cox proportional hazards analysis was used to evaluate patient age at diagnosis, gender, race, and TNM stage. RESULTS: The median overall survival (OS) rates were 36 and 59 months for rare and common pathological groups, respectively, and their respective 10-year OS rates were 31.9% and 42.4%, respectively. The median CSS rate was 61 months for the rare pathological group. Through multivariate analysis, it was found that age, race, T stage, and M stage were independent prognostic risk factors for rare pathological type of urethral cancer. In the age group, the HR ratio of patients aged older than 60 years and younger or equal to 60 years was 2.778 (P<0.001). The HR ratio of other races to Whites was 1.444 (P=0.040). In TNM staging, the HR ratio between T3–T4 and Ta–T2 was 2.386 (P=0.046), and the HR value of M1 and M0 was 5.847 (P<0.001). CONCLUSION: Age, race, T stage, and M stage were predictive of OS and CSS in rare pathological PUC. Dove Medical Press 2018-12-07 /pmc/articles/PMC6289122/ /pubmed/30584373 http://dx.doi.org/10.2147/CMAR.S184197 Text en © 2018 Abudurexiti et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Abudurexiti, Mierxiati
Wang, Jun
Shao, Ning
Wan, Fang-Ning
Zhu, Yao
Dai, Bo
Ye, Ding-Wei
Prognosis of rare pathological primary urethral carcinoma
title Prognosis of rare pathological primary urethral carcinoma
title_full Prognosis of rare pathological primary urethral carcinoma
title_fullStr Prognosis of rare pathological primary urethral carcinoma
title_full_unstemmed Prognosis of rare pathological primary urethral carcinoma
title_short Prognosis of rare pathological primary urethral carcinoma
title_sort prognosis of rare pathological primary urethral carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289122/
https://www.ncbi.nlm.nih.gov/pubmed/30584373
http://dx.doi.org/10.2147/CMAR.S184197
work_keys_str_mv AT abudurexitimierxiati prognosisofrarepathologicalprimaryurethralcarcinoma
AT wangjun prognosisofrarepathologicalprimaryurethralcarcinoma
AT shaoning prognosisofrarepathologicalprimaryurethralcarcinoma
AT wanfangning prognosisofrarepathologicalprimaryurethralcarcinoma
AT zhuyao prognosisofrarepathologicalprimaryurethralcarcinoma
AT daibo prognosisofrarepathologicalprimaryurethralcarcinoma
AT yedingwei prognosisofrarepathologicalprimaryurethralcarcinoma